Compare Merck & Co., Inc. (MRK) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Skyworks Solutions Inc — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Skyworks Solutions Inc trades at $62.75 (market cap $8.99B). The key difference: Merck & Co., Inc. is far larger — about 34.2× Skyworks Solutions Inc's market cap, and Skyworks Solutions Inc pays the higher dividend (4.75%). Which is the better fit depends on your goals.
| MRK | SWKS | |
|---|---|---|
Market Cap | $307.25B | $8.99B |
Sector | Health | Technology |
52-Week High | $129.52 | $83.40 |
52-Week Low | $77.60 | $52.50 |
Enterprise Value | $350.66B | $8.76B |
Dividend Yield | 2.73% | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Skyworks Solutions (SWKS) trades at $62.95, up 6.14% on the day, with a bearish technical signal but strong fundamental valuation metrics including a P/E of 24.91 and P/S of 2.22. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent news highlights ongoing investigations into corporate governance alongside positive coverage of its EV and AI semiconductor innovations.
The stock presents a mixed outlook: analyst consensus is bullish with a $75.88 price target (35 Buy, 23 Hold, 2 Sell), but risks include declining revenue trends (2025: $4.09B, 2026 est: $4.0B), margin compression, and legal scrutiny. Near-term catalysts depend on Q2 earnings beat potential and EV/AI segment growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
